Veracyte(US:VCYT)2025-05-07 21:17Financial Performance - GAAP Gross Profit for the three months ended March 31, 2025 was $79508 thousand, resulting in a GAAP Gross Margin of 695%[42] - Non-GAAP Gross Profit for the three months ended March 31, 2025 was $82613 thousand, yielding a Non-GAAP Gross Margin of 722%[42] - Adjusted EBITDA for the three months ended March 31, 2025, reached $24715 thousand, representing 216% of revenue[47] - GAAP Net Income for the three months ended March 31, 2025, was $7047 thousand, or 62% of revenue[47] - Non-GAAP Net Income for the three months ended March 31, 2025, amounted to $24476 thousand[55] Strategic Initiatives and Product Development - Prosigna LDT is expected to be commercially available in mid-2026[19] - The company submitted a tech assessment to MolDx for MIBC in March 2025, with commercial launch and reimbursement expected in the first half of 2026[22] - NIGHTINGALE pivotal trial enrollment is approximately 95% complete, with completion expected in Q3[28] Operational Expenses - Non-GAAP research and development expenses for the three months ended March 31, 2025, were $15654 thousand[44] - Non-GAAP sales and marketing expenses for the three months ended March 31, 2025, totaled $22496 thousand[44] - Non-GAAP general and administrative expenses for the three months ended March 31, 2025, were $22348 thousand[44]